1-(3-aminopropyl)pyrrolidine-3-carbonitrile | 911300-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(3-aminopropyl)pyrrolidine-3-carbonitrile
• 英文别名: 1-(3-aminopropyl)-3-pyrrolidinecarbonitrile
• CAS: 911300-75-9
• 化学式: C₈H₁₅N₃
• 分子量: 153.227
• InChiKey: GJBIAFDRVNRYLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-chloro-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1-oxide 、 1-(3-aminopropyl)pyrrolidine-3-carbonitrile 在 三乙胺 作用下， 以 乙二醇二甲醚 为溶剂， 反应 16.0h， 以78%的产率得到1-{3-[(1-oxido-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazin-3-yl)amino]propyl}-3-pyrrolidinecarbonitrile
  参考文献：
  名称：

  WO2006/104406

  摘要：

  公开号：
• 作为产物：
  描述：

  吡咯烷-3-甲腈盐酸盐 在 potassium carbonate 、 肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 1-(3-aminopropyl)pyrrolidine-3-carbonitrile
  参考文献：
  名称：

  WO2006/104406

  摘要：

  公开号：

文献信息

• Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
  申请人：Auckland Uniservices Limited

  公开号：US07989451B2

  公开（公告）日：2011-08-02

  The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，涉及它们的制备，以及它们作为缺氧选择性药物和放射增敏剂用于癌症治疗，无论是单独使用还是与放射治疗和/或其他抗癌药物联合使用。
• Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments
  申请人：Hay Michael Patrick

  公开号：US20090186886A1

  公开（公告）日：2009-07-23

  The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，它们的制备以及它们作为低氧选择性药物和放射增敏剂用于癌症治疗，可以单独使用或与放射线和/或其他抗癌药物联合使用。
• Pharmacokinetic/Pharmacodynamic Model-Guided Identification of Hypoxia-Selective 1,2,4-Benzotriazine 1,4-Dioxides with Antitumor Activity: The Role of Extravascular Transport
  作者：Michael P. Hay、Kevin O. Hicks、Frederik B. Pruijn、Karin Pchalek、Bronwyn G. Siim、William R. Wilson、William A. Denny

  DOI：10.1021/jm070670g

  日期：2007.12.13

  Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotriazine 1,4-dioxide (BTO) analogues of TPZ to improve activity against hypoxic cells by increasing extravascular transport. The 6 substituents modified lipophilicity and rates of hypoxic metabolism. 3-Alkylamino substituents increased aqueous solubility and also influenced lipophilicity and hypoxic metabolism. PK/PD model-guided screening was used to select six BTOs for evaluation against hypoxic cells in HT29 human tumor xenografts. All six BTOs were active in vivo, and two provided greater hypoxic cell killing than TPZ because of improved transport and/or plasma PK. This PK/PD model considers two causes of therapeutic failure (limited tumor penetration and poor plasma pharmacokinetics) often not addressed early in drug development and provides a general strategy for selecting candidates for in vivo evaluation during lead optimization.
• TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：EP1866292B1

  公开（公告）日：2010-12-15
• US7989451B2
  申请人：——

  公开号：US7989451B2

  公开（公告）日：2011-08-02